Single-Cell Polyfunctional Strength Applied to Checkpoint & Antibody Based Immunotherapies

Featured Speakers: Will Singleterry, PhD, Director of Business Development, IsoPlexis

What's Inside

In this Webinar we discuss:

Evaluate T cell responses induced by various bispecific T cell engagers across phenotypes

Understand the heterogeneity of TIL polyfunctionality in solid tumors in response to checkpoint inhibitors

Uniquely correlate clinical anti-tumor responses with IsoPlexis data

Optimize combination cancer vaccines in melanoma using model systems

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Watch the Webinar